Biotechnology firm Oxford BioTherapeutics (OBT) has appointed Dr Esteban Pombo-Villar as chief operations officer of the OBT group.
In this position Pombo-Villar will lead OBT’s newly created clinical development operations based in Basel, Switzerland.
The UK-headquartered firm says setting up this operation represents a key milestone in OBT’s global expansion as it progresses its most advanced therapeutic antibody and antibody drug conjugate (ADC) oncology programmes into clinical development.
Dr Pombo-Villar has also become an executive member of OBT’s Board.
Prior to joining OBT, Dr Pombo-Villar was at Novartis for more than 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was head of alliance management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man.
